APLS (Apellis) Forward P/E Multiple

Apellis Pharmaceuticals (APLS) possesses significant pricing power due to the exclusivity of its drug Syfovre. The company's forward P/E ratio history reflects institutional demand dynamics, where the current status is 0.00. The company dictates terms within the rare eye pathology therapy segment, leveraging inelastic demand. Risks are minimized through portfolio diversification with innovative treatments for blood and vision disorders.

apellis.com - APLS Projected Price to Earnings Ratio (period 07/04/2022 - 05/30/2026)

Analytical breakdowns and data insights for company Apellis Corp (APLS)

- current price and projected stock value:

Stock Quotes Apellis|APLS - Fair Value Consensus

- business market valuation indicators:

Market Capitalization Apellis Pharmaceuticals, Inc.|APLS - Total Enterprise Value

- book capitalization information:

Accounting Value per Share Apellis Pharmaceuticals|APLS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio apellis.com|APLS - Company Assets

- debt level and financial liquidity data:

Debt to Equity Apellis Pharmaceuticals|APLS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Apellis Pharmaceuticals|APLS - Company Aggregate Debts|Debt to Book Capitalization Ratio Apellis Pharmaceuticals, Inc.|APLS - Long-Term Liabilities|Company Short-Term Debts Apellis Pharmaceuticals|Quick Liquidity apellis.com

- financial results and valuation multiples details:

APLS - Company Net Income|Expected Profit Apellis Pharmaceuticals|APLS - Price to Earnings Ratio|Forward P/E Multiple Apellis Pharmaceuticals Inc|APLS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apellis Pharmaceuticals, Inc.|APLS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Apellis Pharmaceuticals|APLS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months apellis.com|APLS - Earnings per share trend in current year|Earnings growth forecast for next year Apellis Pharmaceuticals

Comprehensive company analysis:APLS Apellis

A conservative analysis of Apellis Pharmaceuticals (APLS) requires comparing the current share price with projected forward earnings to avoid overpaying for the asset. By examining the company's expected P/E multiple, an investor can see how the diversification of therapeutic platforms in ophthalmology and systemic diseases mitigates risks, stabilizing future revenues and creating a more resilient investment profile for the business.

Competitor analysis for Apellis Pharmaceuticals